Experiencia en el manejo de malformaciones linfáticas macroquísticas con alcohol y microquísticas con bleomicina / Experience In the Management of Macrocystic Lymphatic Malformations with Alcohol and Microcystic Malformations with Bleomycin

Las malformaciones linfáticas son anomalías raras de flujo lento y bajo que se presentan en 1 de 6.000 a 1 en 16.000 recién nacidos vivos. Las malformaciones quísticas se clasifican según su tamaño en macroquísticas, microquísticas o mixtas. Esta clasificación tiene impacto sobre el tratamiento y el pronóstico. Las malformaciones linfáticas macroquísticas tienen mejor respuesta al tratamiento, mientras que las microquísticas son difíciles de tratar y con frecuencia recidivan. El objetivo de este trabajo es describir los resultados obtenidos en pacientes con malformaciones linfáticas macro y microquísticas intervenidos con escleroterapia utilizando alcohol y bleomicina, respectivamente. Se realizó un estudio descriptivo de pacientes con malformaciones linfáticas tratadas en el Servicio de Radiología. Se incluyeron 38 pacientes, de los cuales 24 tenían lesiones macroquísticas, 10, microquísticas y 4, mixtas. El 68 % fueron tratados con alcohol y el 32 % con bleomicina. El tratamiento mostró una resolución excelente en 5 pacientes, 25 tuvieron reducción del tamaño de la lesión entre 50 y 90 %, 13 % mostró una respuesta pobre, y solo en un 7 % hubo crecimiento, a pesar del tratamiento esclerosante. De lo anterior se concluye que el tratamiento percutáneo es seguro, reduce el tamaño de las lesiones y hay pocas complicaciones informadas. Se podría utilizar como tratamiento inicial, antes de considerar una cirugía.

Lymphatic malformations are rare slow and low flow abnormalities that occur in 1 of 6,000 to 1 in 16,000 live newborns. Cystic malformations are classified according to their size as macrocystic, microcystic, or mixed. This classification has an impact on treatment and prognosis. Macrocystic lymphatic malformations have a better response to treatment, while microcystic malformations are difficult to treat and frequently recur. The objective of this study is to describe the results obtained in patients with macro and microcystic lymphatic malformations who underwent sclerotherapy using alcohol and Bleomycin, respectively. A descriptive study of patients with lymphatic malformations treated in the Radiology Service of the National Institute of Pediatrics was carried out during the period from 2014 to 2016. Thirty-eight patients were included, 24 with macrocystic, 10 microcystic and 4 mixed lesions. 68% were treated with alcohol and 32% of the patients were treated with Bleomycin. The treatment showed excellent resolution in 5 patients, 25 patients had a lesion size reduction between 50 and 90%, 13% had a poor response, and only 7% had growth despite sclerosing treatment. From the above we conclude that percutaneous treatment is safe, reduces the size of the lesions and there are few reported complications. It could be used as initial treatment before considering surgery.

Clinical impact of a 6-week preoperative very low calorie diet on body weight and liver size in morbidly obese patients.

BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (LRYGB) may be a technically challenging surgical technique when features such as thick abdominal wall and increased liver volume are present. Very low calorie diets in the form of liquid meal replacements given 6 weeks prior to surgery have proven to decrease liver volume. The aim of our study was to assess the effect of a 6-week preoperative low calorie/regular diet on liver volume and body weight in morbidly obese patients. METHODS: A pilot study was carried out in 20 morbidly obese patients with an 800-kcal diet for 6 weeks. They were followed weekly to ensure proper compliance. CT scan was used for determining liver volume every 2 weeks in order to assess the impact of the diet. Baseline values were taken as controls for every patient as tied measures. Statistical analysis was suitable to variable scaling and performed using SPSS v. 20.0. Parametric and non-parametric test for tied measures were done. Any p value lesser than 0.05 or 5% was considered as statistically significant. RESULTS: Twenty patients adhered to the diet intervention for 6 weeks prior to LRYGB. Median ± SD age was 34.5 ± 11.5 years and 17 were female (85%). Heart rate and blood pressure did not vary across the study. Initial median ± SD BMI was 46.02 ± 5.29 kg/m2 (range 38.7-54.8). Repeated and tied measurements across the 6 weeks of treatment within individuals resulted statistically significant for reducing BMI (p < 0.0001). CT scan assessed liver volume initially as a control and in weeks 2, 4 and 6. Parametric and non-parametric assessment for multiple measurements also showed statistical significance among these values (p < 0.0001). Diet tolerability was additionally evaluated with a questionnaire showing more than 80% of acceptability with discrete rates of nausea (15%) and diarrhoea (15%). CONCLUSIONS: Based on our results, we demonstrated that a very low calorie diet with home ingredients is capable for effectively reducing body weight and liver size in morbidly obese patients. This relatively short intervention (4 to 6 weeks) was accomplished in all our patients with a high frequency of compliance and a low rate of secondary effects.

Radiofrequency ablation of a hepatic neoplasm in a patient with an abdominal pacemaker.

We present the case of a 52 year-old male with a history of C-hepatitis and two liver neoplastic lesions treated by radiofrequency (RF) ablation. The patient wears an abdominally-implanted unipolar VVI pacemaker that did not show any signs of interference during RF pulses. We describe the procedure performed and discuss the present knowledge regarding the possibilities of RF interference with the normal pacemaker functioning in several settings related to abdominal RF treatments.